Northern Trust Corp Has $120.69 Million Stock Position in Relx Plc $RELX

Key Points

• Northern Trust Corp increased its stake in Relx Plc by 9.2%, owning approximately 2.39 million shares worth $120.69 million as of the latest reporting period.
• Relx recently announced a semi-annual dividend of $0.2634 per share, which is set to be paid on September 16th, representing a yield of 170.0%.
• Wall Street analysts have upgraded Relx’s rating from "hold" to "buy", with the company currently holding an average rating of "Buy" from several analysts.

Northern Trust Corp increased its stake in Relx Plc (NYSE:RELX - Free Report) by 9.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,394,097 shares of the technology company's stock after acquiring an additional 202,509 shares during the quarter. Northern Trust Corp owned approximately 0.13% of Relx worth $120,686,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. ABC Arbitrage SA grew its holdings in shares of Relx by 40.1% in the 1st quarter. ABC Arbitrage SA now owns 194,197 shares of the technology company's stock worth $9,789,000 after acquiring an additional 55,579 shares during the last quarter. Pandora Wealth Inc. purchased a new position in shares of Relx during the first quarter valued at $757,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Relx by 103.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 106,220 shares of the technology company's stock valued at $5,355,000 after buying an additional 54,062 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Relx by 19.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 18,957 shares of the technology company's stock valued at $956,000 after buying an additional 3,092 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in shares of Relx by 8.7% during the first quarter. Neuberger Berman Group LLC now owns 279,344 shares of the technology company's stock valued at $14,043,000 after buying an additional 22,249 shares in the last quarter. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Relx from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. Based on data from MarketBeat, Relx currently has an average rating of "Buy".

Relx Stock Down 0.9%

RELX traded down $0.43 during trading on Friday, reaching $46.54. 341,934 shares of the stock traded hands, compared to its average volume of 886,974. The stock has a market cap of $85.37 billion, a price-to-earnings ratio of 25.02, a price-to-earnings-growth ratio of 3.12 and a beta of 0.88. Relx Plc has a fifty-two week low of $44.19 and a fifty-two week high of $56.33. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42. The stock's 50-day simple moving average is $51.29 and its two-hundred day simple moving average is $51.41.

Relx Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, September 16th. Investors of record on Friday, August 8th will be given a dividend of $0.2634 per share. The ex-dividend date of this dividend is Friday, August 8th. This represents a yield of 170.0%. Relx's dividend payout ratio (DPR) is presently 28.49%.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.